目的：探讨普拉洛芬治疗角结膜干燥症的疗效、自觉症状评分及安全性。

方法：选取2014-01/2016-05我院收治的角结膜干燥症患者100例200眼，根据治疗方法不同分为对照组和研究组，每组患者各50例100眼。对照组患者给予人工泪液治疗，研究组患者给予人工泪液联合普拉洛芬滴眼液治疗，观察并分析两组患者的临床疗效。

结果：研究组患者治疗后临床治愈20例40眼，有效26例52眼，总有效率为92.0%，高于对照组患者，差异有统计学意义(P<0.05)。两组患者治疗后自觉症状、BUT及FL评分均较治疗前改善(P<0.05)，但SⅠt比较差异无统计学意义(P>0.05)。研究组患者治疗后自觉症状和FL评分均低于对照组，BUT评分高于对照组(P<0.05)。两组患者治疗后泪液中TNF-α、IL-6及IL-1β水平均较治疗前降低，且研究组患者泪液中TNF-α、IL-6及IL-1β水平均低于对照组患者(P<0.05)。两组患者不良反应情况比较，差异无统计学意义(P=1.00)。

结论：普拉洛芬治疗角结膜干燥症疗效显著，可改善症状和体征，控制感染，安全性高。

METHODS: Totally 100 cases(200 eyes)of keratoconjunctivitis sicca treated in our hospital in January 2014 to May 2016 were divided into control group and study group according to different treatment methods. The patients in the control group were treated with artificial tear and the patients in the study group were treated with artificial tear combined with pranoprofen eye drops. The clinical effects of the two groups were observed and analyzed.

RESULTS: In the study group, 20 cases(40 eyes)were cured, 26 cases(52 eyes)were effective. The total effective rate was 92.0% higher than that of the control group. The difference was statistically significant(P<0.05). The symptoms, BUT and FL scores of two groups after treatment were better than before treatment(P<0.05), but SⅠT score was not statistically significant(P>0.05). The symptoms and FL scores of study group after treatment were lower than those of the control group after treatment, the BUT score was higher than that of the control group(P<0.05). After treatment, the levels of TNF-α, IL-6 and IL-1β in the two groups were lower than those before treatment, and the levels of TNF-α, IL-6 and IL-1β in the study group were significantly lower than in the control group(P<0.05). the difference of patients with adverse reactions between two groups was not statistically significant(P=1.00).

CONCLUSION: Pranoprofen has a significant effect on the treatment of keratoconjunctivitis sicca, can improve symptoms and signs, control the infection, with high safety.